Evidence map›Paper›PMID 26086941›Full record

Trial reportCritical care medicine2015

Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial.

Sadeq A Quraishi, Gennaro De Pascale, Joseph S Needleman, Harumasa Nakazawa, Masao Kaneki, Ednan K Bajwa, Carlos A Camargo, Ishir Bhan

2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Critical care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 89 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 13 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02868827 phase2 / phase3terminatednot on this mapstarted 2017, after this paper: background citation

Cholecalciferol Supplementation in Critically Ill Patients With Severe Vitamin D Deficiency in Intensive Care Unit- A Randomized Controlled Trial.

TypeinterventionalSponsorKing Abdullah Medical CityRan2017 to 2019Enrolled127ConditionsVitamin D Deficiency, Critical IllnessArmsCholecalciferol, Milk (Nestle)
NCT04915963 phase3completednot on this mapstarted 2016, after this paper: background citation

Effect of a Single Mega-dose of Vitamin D3 Supplementation on Clinical Course in Non-deficient Patients Admitted in Intensive Care Unit

TypeinterventionalSponsorAssociation Tunisienne d'Etude & de Recherche sur l'AthéroscléroseRan2016 to 2019Enrolled340ConditionsDietary Supplements, Intensive Care Unit, Vitamin D Deficiency, Vitamin D ToxicityArmsVitamin D supplementation
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 13 syntheses or guidelines pooled it, 199 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Early High-Dose Vitamin DThe New England journal of medicine · 2019
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Impact of high-dose vitamin DNutrition (Burbank, Los Angeles County, Calif.) · 2017
    Trial

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sadeq A Quraishi1Harvard Medical School, Boston, MA. 2Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA. 3Shriners Hospital for Children, Boston, MA. 4Department of Medicine, Massachusetts General Hospital, Boston, MA. 5Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA. 6Harvard School of Public Health, Boston, MA.
Gennaro De Pascale
Joseph S Needleman
Harumasa Nakazawa
Masao Kaneki
Ednan K Bajwa
Carlos A Camargo
Ishir Bhan
Massachusetts General Hospital · USHarvard University · USShriners Hospitals for Children - Boston · US

Funding

Research Training for AnesthetistsT32GM007592 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI STUART A FORMAN · 1985 to 2026
$11.8M
Prospective Cohort Study of Severe Bronchiolitis and Risk of Recurrent WheezingU01AI087881 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CAMARGO, CARLOS ARTURO · 2011 to 2016
$6.2M
Effects of vitamin D and omega-3 fatty acids on infectious diseases and hCAP18R01AI093723 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI CAMARGO, CARLOS ARTURO · 2011 to 2015
$4.0M
Use of advanced imaging techniques to improve diagnostic methods for ARDSR01HL119344 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI THOMPSON, BOYD TAYLOR · 2014 to 2018
$3.3M
Human Cathelicidin (hCAP18) in Chronic Kidney DiseaseK23DK081677 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BHAN, ISHIR · 2009 to 2013
$684k
NCATS NIH HHS L30 TR001257NHLBI NIH HHS R01 HL119344NIAID NIH HHS R01 AI093723NIAID NIH HHS U01 AI087881NIDDK NIH HHS K23 DK081677NIGMS NIH HHS P50GM02700NIGMS NIH HHS T32 GM007592
6 · The paper itself

Abstract

objectivesTo compare changes in vitamin D status and cathelicidin (LL-37) levels in septic ICU patients treated with placebo versus cholecalciferol.

designRandomized, placebo-controlled, trial.

settingMedical and surgical ICUs of a single teaching hospital in Boston, MA. PATIENTS: Thirty adult ICU patients.

interventionsPlacebo (n = 10) versus 200,000 IU cholecalciferol (n = 10) versus 400,000 IU cholecalciferol (n = 10), within 24 hours of new-onset severe sepsis or septic shock. MEASUREMENTS AND MAIN

resultsBlood samples were obtained at baseline (day 1) and on days 3, 5, and 7, to assess total 25-hydroxyvitamin D, as well as vitamin D-binding protein and albumin to calculate bioavailable 25-hydroxyvitamin D. Plasma LL-37 and high-sensitivity C-reactive protein levels were also measured. At baseline, median (interquartile range) plasma 25-hydroxyvitamin D was 17 ng/mL (13-22 ng/mL) and peaked by day 5 in both intervention groups. Groups were compared using Kruskal-Wallis tests. Relative to baseline, on day 5, median change in biomarkers for placebo, 200,000 IU cholecalciferol, and 400,000 IU cholecalciferol groups, respectively, were as follows: 1) total 25-hydroxyvitamin D, 3% (-3% to 8%), 49% (30-82%), and 69% (55-106%) (p < 0.001); 2) bioavailable 25-hydroxyvitamin D, 4% (-8% to 7%), 45% (40-70%), and 96% (58-136%) (p < 0.01); and 3) LL-37: -17% (-9% to -23%), 4% (-10% to 14%), and 30% (23-48%) (p = 0.04). Change in high-sensitivity C-reactive protein levels did not differ between groups. A positive correlation was observed between bioavailable 25-hydroxyvitamin D and LL-37 (Spearman ρ = 0.44; p = 0.03) but not for total 25-hydroxyvitamin D and LL-37.

conclusionsHigh-dose cholecalciferol supplementation rapidly and safely improves 25-hydroxyvitamin D and bioavailable 25-hydroxyvitamin D levels in patients with severe sepsis or septic shock. Changes in bioavailable 25-hydroxyvitamin D are associated with concomitant increases in circulating LL-37 levels. Larger trials are needed to verify these findings and to assess whether optimizing vitamin D status improves sepsis-related clinical outcomes.

Indexed as

Dietary SupplementsAdultAntimicrobial Cationic PeptidesBiomarkersCalcifediolCathelicidinsCholecalciferolC-Reactive ProteinFemaleHospitals, TeachingHumansIntensive Care UnitsMaleMiddle AgedSepsisSerum Albumin25-hydroxyvitamin DAntimicrobial Cationic PeptidesBiomarkersCalcifediolCathelicidinsCholecalciferolC-Reactive ProteinSerum AlbuminVitamin D

Identifiers

PMID26086941
PMCPMC4537665
OpenAlexW1794529779

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.